One-Shot vs. daily doses: trial aims to simplify serious fungal infection treatment
NCT ID NCT07261150
Summary
This study aims to find better ways to treat moderate to severe histoplasmosis, a serious fungal infection. It will test if a single high-dose intravenous treatment works as well as the standard daily lower doses. It will also test if a newer oral drug (posaconazole) or a shorter 6-month treatment plan is as safe and effective as the current standard 12-month plan for people with HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOPLASMOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil
Contact Email: •••••@•••••
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.